Latest Articles

Publication Date
All News Scientific
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Read Full Article
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress

Published: June 1, 2026, 8 p.m.
Read Full Article
Voice of the Voter: Watch CD1 Republican primary debate tonight on NEWS CENTER Maine - newscentermaine.com

Voice of the Voter: Watch CD1 Republican primary debate tonight on NEWS CENTER Maine newscentermaine.com

Published: May 28, 2026, 8:22 p.m.
Read Full Article
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance

Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Yahoo Finance

Published: May 23, 2026, 12:01 p.m.
Read Full Article
Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge - Cureus

Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge Cureus

Published: May 21, 2026, 4:13 p.m.
Read Full Article
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.
Read Full Article
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Read Full Article
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!